Chief Medical Editor's Page: DES Evolution

By Ted E. Feldman, MD, FSCAI

Novel Drug-Eluting Coronary Stents Nearing Approval in the United States

New stent platforms may offer enhanced performance, safety, and efficacy characteristics.

By Dean J. Kereiakes, MD, FACC

New DES Platforms

Does the metal alloy matter?

By Barbara Huibregtse, DVM, and Juan F. Granada, MD

Drug-Eluting Balloon Technology

This promising new technology represents what might be an alternative option for treating coronary and peripheral arterial disease.

By Raffaella Marzullo, MD; Alessandro Aprile, MD; Giuseppe Biondi-Zoccai, MD; Luigi Politi, MD; Chiara Leuzzi, MD; and Giuseppe M. Sangiorgi, MD, FESC, FSCAI

Management of In-Stent Restenosis After DES Use

Insights on current mechanisms and strategies for treatment.

By Vineet Bhatia, MD, DM, DNB, MNAMS, and Upendra Kaul, MD, DM, FCSI, FSCAI, FACC, FAMS

Are New DES Designs Safer?

Changes in stent platform, polymer, and drug components have led to improved outcomes.

By Ashwani Sastry, MD, and Mitchell W. Krucoff, MD, FACC, FSCAI, FAHA

Is optical coherence tomography effective in imaging intravascular thrombus?

Sponsored by St. Jude Medical

By Sammy Elmariah, MD, MPH, and Ik-Kyung Jang, MD, PhD,

The FDA Panel Meeting to Discuss Transcatheter Aortic Valve Implantation

A first-hand European perspective.

By Martyn Thomas, MD, FRCP

How Has the DES Market Changed?

Mark A. Turco, MD, FACC, an interventional cardiologist turned chief medical officer, offers a unique perspective regarding the pressures currently facing the DES market.

An Interview With Frederick St. Goar, MD

The interventional cardiologist who founded Evalve, Inc., the company that developed the MitraClip device, shares his thoughts on the latest mitral regurgitation data and his hands-on approach to the development of novel interventional cardiology devices.